Trial record 2 of 26 for:    bone health, calcium, osteoporosis | Child

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Purdue University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Information provided by:
Purdue University
ClinicalTrials.gov Identifier:
NCT00244907
First received: October 25, 2005
Last updated: July 27, 2010
Last verified: July 2010
  Purpose

Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.


Condition Intervention Phase
Osteoporosis
Osteopenia
Drug: Soy Phytoestrogens
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Metabolism and Bone Health

Resource links provided by NLM:


Further study details as provided by Purdue University:

Primary Outcome Measures:
  • Urinary markers of bone resorption; measured at the end of each treatment phase [ Time Frame: Every 50 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Serum markers of bone resorption and calcium absorption; measured at the end of each treatment phase [ Time Frame: Every 50 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: January 2006
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Soy Phytoestrogens
    Soy Phytoestrogens
Detailed Description:

Estrogen is a hormone that activates bone-forming cells and prevents calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may accelerate bone breakdown and inhibit the body's ability to create new bone, thereby leading to bone loss and possibly osteoporosis. Various treatments have been developed to decrease bone loss in post-menopausal women. Actonel, for example, is an FDA-approved drug used to help prevent bone loss.

Phytoestrogens are plant compounds with a structure similar to estrogen. They have also been shown to help reduce the negative effects of menopause. Isoflavones are a particular type of phytoestrogens that are found in soy plants and may act like estrogen in providing possible protection against bone loss. This study will compare the effects of isoflavones (including genistein, a type of isoflavone) versus Actonel on calcium absorption and bone loss in post-menopausal women.

Participants in this double-blind cross-over study will first complete a screening process, which will include answering questions about their health habits, medical history, physical activity, and food patterns. They will then eat one soy bar daily for 3 days. On Day 4, a urine sample will be taken to assess their ability to metabolize phytoestrogen from soybeans. Participants will be randomly assigned to a specific treatment order. Participants will receive 1-4 unique soy isoflavones, followed by Actonel. Treatment phases will be separated by a 50-day washout period. All participants will also take calcium and vitamin D supplements throughout the study. Assessments will include bone density measurements, calcium absorption tests, and blood and urine tests. The study will last approximately 2.5 years.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • At least 4 years post-menopausal

Exclusion Criteria:

  • Not currently taking estrogen replacement therapy or undergoing any treatment for osteoporosis
  • Diagnosis of breast cancer
  • Results of mammogram suggesting breast cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00244907

Locations
United States, Indiana
Purdue University
West Lafayette, Indiana, United States, 47907
Sponsors and Collaborators
Purdue University
Investigators
Principal Investigator: Connie M. Weaver, PhD Purdue University
  More Information

Additional Information:
Publications:
Responsible Party: Connie Weaver, PhD, Purdue University
ClinicalTrials.gov Identifier: NCT00244907     History of Changes
Other Study ID Numbers: P50 AT000477-06, P50AT000477-06
Study First Received: October 25, 2005
Last Updated: July 27, 2010
Health Authority: United States: Federal Government

Keywords provided by Purdue University:
Bone Resorption
Phytoestrogens
Calcium
Genistein
Equol

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Osteoporosis
Bone Diseases
Musculoskeletal Diseases
Phytoestrogens
Estrogens, Non-Steroidal
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013